A One Year, Open-label, Study to Evaluate the Safety and Tolerability of Risperidone Implants as a Maintenance Treatment in Patients With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Braeburn Pharmaceuticals
- 26 Apr 2017 Results from this trial are expected later in 2017, according to a Braeburn Pharmaceuticals media release.
- 07 Oct 2016 Planned number of patients changed from 100 to 145.
- 07 Oct 2016 Status changed from recruiting to active, no longer recruiting.